Cabiralizumab

Drug Profile

Cabiralizumab

Alternative Names: FPA-008

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Five Prime Therapeutics
  • Developer Bristol-Myers Squibb; Five Prime Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Colony stimulating factor receptor antagonists; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pigmented villonodular synovitis
  • Phase I Solid tumours
  • Preclinical Cancer
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 24 Jan 2017 Cabiralizumab receives Orphan Drug status for Pigmented villonodular synovitis in European Union
  • 04 Oct 2016 Five Prime Therapeutics initiates enrolment in a phase Ib trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA (IV)
  • 13 Sep 2016 Discontinued - Phase-I for Rheumatoid arthritis in Netherlands, Hungary and Poland (IV) (NCT01962337)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top